Which has better earnings and valuation, NGNE or HUMA?

Humacyte has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neurogene $930K 564.72 -$90.35M -$4.55 N/A Humacyte $2.04M 75.20 -$40.83M -$0.57 N/A

Is NGNE or HUMA more profitable?

Neurogene has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. Neurogene's return on equity of -37.88% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Neurogene N/A -37.88% -34.70% Humacyte -4,836.06% -2,914.18% -89.45%

Does the media refer more to NGNE or HUMA?

In the previous week, Humacyte had 4 more articles in the media than Neurogene. MarketBeat recorded 6 mentions for Humacyte and 2 mentions for Neurogene. Neurogene's average media sentiment score of 1.16 beat Humacyte's score of 0.27 indicating that Neurogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Humacyte 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CTMX or HUMA?

In the previous week, CytomX Therapeutics had 5 more articles in the media than Humacyte. MarketBeat recorded 11 mentions for CytomX Therapeutics and 6 mentions for Humacyte. CytomX Therapeutics' average media sentiment score of 1.24 beat Humacyte's score of 0.27 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Humacyte 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RLMD or HUMA?

In the previous week, Relmada Therapeutics had 3 more articles in the media than Humacyte. MarketBeat recorded 9 mentions for Relmada Therapeutics and 6 mentions for Humacyte. Relmada Therapeutics' average media sentiment score of 1.29 beat Humacyte's score of 0.27 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Humacyte 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, ALT or HUMA?

Humacyte has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Altimmune $36K 15,801.01 -$88.09M -$0.93 N/A Humacyte $2.04M 75.20 -$40.83M -$0.57 N/A

Is ALT or HUMA more profitable?

Humacyte has a net margin of -4,836.06% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Altimmune -214,860.98% -42.57% -35.57% Humacyte -4,836.06% -2,914.18% -89.45%

Does the media refer more to ALT or HUMA?

In the previous week, Altimmune had 8 more articles in the media than Humacyte. MarketBeat recorded 14 mentions for Altimmune and 6 mentions for Humacyte. Humacyte's average media sentiment score of 0.27 beat Altimmune's score of -0.36 indicating that Humacyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 7 Negative mention(s) 1 Very Negative mention(s) Neutral Humacyte 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor EIKN or HUMA?

In the previous week, Humacyte had 3 more articles in the media than Eikon Therapeutics. MarketBeat recorded 6 mentions for Humacyte and 3 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 0.62 beat Humacyte's score of 0.27 indicating that Eikon Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Humacyte 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Humacyte (HUMA) Competitors

$0.69 +0.03 (+4.99%)

As of 12:51 PM Eastern

Compare

HUMA vs. NGNE, CTMX, RLMD, ALT, and EIKN

Should you buy Humacyte stock or one of its competitors? MarketBeat compares Humacyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Humacyte include Neurogene (NGNE), CytomX Therapeutics (CTMX), Relmada Therapeutics (RLMD), Altimmune (ALT), and Eikon Therapeutics (EIKN).

How does Humacyte compare to Neurogene?

Neurogene (NASDAQ:NGNE) and Humacyte (NASDAQ:HUMA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Neurogene has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. Neurogene's return on equity of -37.88% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Humacyte	-4,836.06%	-2,914.18%	-89.45%

In the previous week, Humacyte had 4 more articles in the media than Neurogene. MarketBeat recorded 6 mentions for Humacyte and 2 mentions for Neurogene. Neurogene's average media sentiment score of 1.16 beat Humacyte's score of 0.27 indicating that Neurogene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Humacyte	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neurogene currently has a consensus target price of $84.83, suggesting a potential upside of 155.21%. Humacyte has a consensus target price of $6.25, suggesting a potential upside of 804.49%. Given Humacyte's higher probable upside, analysts clearly believe Humacyte is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Humacyte has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	564.72	-$90.35M	-$4.55	N/A
Humacyte	$2.04M	75.20	-$40.83M	-$0.57	N/A

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 11.7% of Neurogene shares are owned by insiders. Comparatively, 3.1% of Humacyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Neurogene has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.54, suggesting that its share price is 154% more volatile than the broader market.

Summary

Neurogene beats Humacyte on 9 of the 17 factors compared between the two stocks.

How does Humacyte compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Humacyte (NASDAQ:HUMA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

CytomX Therapeutics has higher revenue and earnings than Humacyte. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	6.98	-$17.37M	-$0.41	N/A
Humacyte	$2.04M	75.20	-$40.83M	-$0.57	N/A

CytomX Therapeutics has a net margin of -166.40% compared to Humacyte's net margin of -4,836.06%. CytomX Therapeutics' return on equity of -36.61% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Humacyte	-4,836.06%	-2,914.18%	-89.45%

In the previous week, CytomX Therapeutics had 5 more articles in the media than Humacyte. MarketBeat recorded 11 mentions for CytomX Therapeutics and 6 mentions for Humacyte. CytomX Therapeutics' average media sentiment score of 1.24 beat Humacyte's score of 0.27 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Humacyte	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CytomX Therapeutics presently has a consensus price target of $12.10, indicating a potential upside of 287.20%. Humacyte has a consensus price target of $6.25, indicating a potential upside of 804.49%. Given Humacyte's higher probable upside, analysts clearly believe Humacyte is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

CytomX Therapeutics has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.54, meaning that its stock price is 154% more volatile than the broader market.

Summary

CytomX Therapeutics beats Humacyte on 13 of the 17 factors compared between the two stocks.

How does Humacyte compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Humacyte (NASDAQ:HUMA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by insiders. Comparatively, 3.1% of Humacyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Relmada Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 132.78%. Humacyte has a consensus target price of $6.25, indicating a potential upside of 804.49%. Given Humacyte's higher possible upside, analysts plainly believe Humacyte is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Humacyte has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Humacyte	$2.04M	75.20	-$40.83M	-$0.57	N/A

Relmada Therapeutics has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, Humacyte has a beta of 2.54, meaning that its share price is 154% more volatile than the broader market.

Relmada Therapeutics has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. Relmada Therapeutics' return on equity of -71.22% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Humacyte	-4,836.06%	-2,914.18%	-89.45%

In the previous week, Relmada Therapeutics had 3 more articles in the media than Humacyte. MarketBeat recorded 9 mentions for Relmada Therapeutics and 6 mentions for Humacyte. Relmada Therapeutics' average media sentiment score of 1.29 beat Humacyte's score of 0.27 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Humacyte	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Relmada Therapeutics beats Humacyte on 8 of the 15 factors compared between the two stocks.

How does Humacyte compare to Altimmune?

Altimmune (NASDAQ:ALT) and Humacyte (NASDAQ:HUMA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

Altimmune currently has a consensus price target of $15.71, indicating a potential upside of 437.24%. Humacyte has a consensus price target of $6.25, indicating a potential upside of 804.49%. Given Humacyte's stronger consensus rating and higher possible upside, analysts plainly believe Humacyte is more favorable than Altimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

78.1% of Altimmune shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 1.6% of Altimmune shares are held by company insiders. Comparatively, 3.1% of Humacyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Altimmune has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, Humacyte has a beta of 2.54, indicating that its stock price is 154% more volatile than the broader market.

Humacyte has a net margin of -4,836.06% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
Humacyte	-4,836.06%	-2,914.18%	-89.45%

In the previous week, Altimmune had 8 more articles in the media than Humacyte. MarketBeat recorded 14 mentions for Altimmune and 6 mentions for Humacyte. Humacyte's average media sentiment score of 0.27 beat Altimmune's score of -0.36 indicating that Humacyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	7 Negative mention(s)	1 Very Negative mention(s)	Neutral
Humacyte	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Humacyte has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$36K	15,801.01	-$88.09M	-$0.93	N/A
Humacyte	$2.04M	75.20	-$40.83M	-$0.57	N/A

Summary

Humacyte beats Altimmune on 10 of the 16 factors compared between the two stocks.

How does Humacyte compare to Eikon Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and Humacyte (NASDAQ:HUMA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

44.7% of Humacyte shares are held by institutional investors. 3.1% of Humacyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Eikon Therapeutics presently has a consensus target price of $25.20, indicating a potential upside of 172.90%. Humacyte has a consensus target price of $6.25, indicating a potential upside of 804.49%. Given Humacyte's stronger consensus rating and higher probable upside, analysts plainly believe Humacyte is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Humacyte had 3 more articles in the media than Eikon Therapeutics. MarketBeat recorded 6 mentions for Humacyte and 3 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 0.62 beat Humacyte's score of 0.27 indicating that Eikon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Humacyte	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eikon Therapeutics has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. Eikon Therapeutics' return on equity of 0.00% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
Humacyte	-4,836.06%	-2,914.18%	-89.45%

Eikon Therapeutics has higher earnings, but lower revenue than Humacyte. Eikon Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	N/A	-$2.46	N/A
Humacyte	$2.04M	75.20	-$40.83M	-$0.57	N/A

Summary

Humacyte beats Eikon Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Humacyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HUMA vs. The Competition

Export

Metric	Humacyte	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$153.64M	$3.52B	$6.80B	$12.66B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-1.21	7.38	282.16	25.05
Price / Sales	75.20	1,220.59	576.18	79.91
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	34.55	16.79	10.96	6.18
Net Income	-$40.83M	-$12.56M	$3.49B	$347.61M
7 Day Performance	2.51%	-0.84%	0.45%	0.71%
1 Month Performance	-2.68%	-7.59%	-4.26%	-3.75%
1 Year Performance	-69.69%	49.20%	63.09%	20.17%

Humacyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HUMA Humacyte	3.513 of 5 stars	$0.69 +5.8%	$6.25 +804.5%	-71.3%	$153.64M	$2.04M	N/A	150	Upcoming Earnings Analyst Upgrade
NGNE Neurogene	3.4231 of 5 stars	$34.62 -0.8%	$84.83 +145.0%	+51.0%	$551.49M	$930K	N/A	90	News Coverage Positive News Upcoming Earnings
CTMX CytomX Therapeutics	2.6461 of 5 stars	$3.25 +0.3%	$12.10 +272.3%	+31.9%	$551.41M	$76.20M	N/A	170	News Coverage Positive News Upcoming Earnings
RLMD Relmada Therapeutics	2.3284 of 5 stars	$5.20 +0.4%	$12.00 +130.8%	+799.4%	$543.33M	N/A	N/A	10	Positive News Upcoming Earnings
ALT Altimmune	2.0016 of 5 stars	$2.96 +6.9%	$15.71 +430.9%	-21.3%	$538.69M	$40K	N/A	50	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HUMA) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Humacyte (HUMA) Competitors

HUMA vs. NGNE, CTMX, RLMD, ALT, and EIKN

How does Humacyte compare to Neurogene?

Summary

How does Humacyte compare to CytomX Therapeutics?

Summary

How does Humacyte compare to Relmada Therapeutics?

Summary

How does Humacyte compare to Altimmune?

Summary

How does Humacyte compare to Eikon Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HUMA vs. The Competition

Humacyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Humacyte (HUMA) Competitors

HUMA vs. NGNE, CTMX, RLMD, ALT, and EIKN

How does Humacyte compare to Neurogene?

Is NGNE or HUMA more profitable?

Does the media refer more to NGNE or HUMA?

Do analysts prefer NGNE or HUMA?

Which has better earnings and valuation, NGNE or HUMA?

Do institutionals and insiders have more ownership in NGNE or HUMA?

Which has more volatility and risk, NGNE or HUMA?

Summary

How does Humacyte compare to CytomX Therapeutics?

Which has better earnings & valuation, CTMX or HUMA?

Is CTMX or HUMA more profitable?

Does the media refer more to CTMX or HUMA?

Do analysts rate CTMX or HUMA?

Do institutionals & insiders have more ownership in CTMX or HUMA?

Which has more risk and volatility, CTMX or HUMA?

Summary

How does Humacyte compare to Relmada Therapeutics?

Do insiders & institutionals have more ownership in RLMD or HUMA?

Do analysts recommend RLMD or HUMA?

Which has preferable valuation & earnings, RLMD or HUMA?

Which has more risk & volatility, RLMD or HUMA?

Is RLMD or HUMA more profitable?

Does the media refer more to RLMD or HUMA?

Summary

How does Humacyte compare to Altimmune?

Do analysts prefer ALT or HUMA?

Do insiders and institutionals have more ownership in ALT or HUMA?

Which has more volatility and risk, ALT or HUMA?

Is ALT or HUMA more profitable?

Does the media refer more to ALT or HUMA?

Which has preferable earnings & valuation, ALT or HUMA?

Summary

How does Humacyte compare to Eikon Therapeutics?

Do insiders & institutionals have more ownership in EIKN or HUMA?

Do analysts prefer EIKN or HUMA?

Does the media favor EIKN or HUMA?

Is EIKN or HUMA more profitable?

Which has stronger valuation & earnings, EIKN or HUMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HUMA vs. The Competition

Humacyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools